Neurotech International Ltd. Stock Analysis NTI.AX

Neurotech International Ltd. engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2016-11-04. The firm focuses predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. The company has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD). In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved. The Company’s subsidiaries include AAT Research Ltd and AAT Medical Ltd.